Pith. sign in

REVIEW

Drug prescription clusters in the UK Biobank: An assessment of drug-drug interactions and patient outcomes in a large patient cohort

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2207.08665 v2 pith:QP5RT55M submitted 2022-07-18 q-bio.QM

Drug prescription clusters in the UK Biobank: An assessment of drug-drug interactions and patient outcomes in a large patient cohort

classification q-bio.QM
keywords drugpatientbiobankdrugsoutcomespolypharmacyprescriptionclusters
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

In recent decades, there has been an increase in polypharmacy, the concurrent administration of multiple drugs per patient. Studies have shown that polypharmacy is linked to adverse patient outcomes and there is interest in elucidating the exact causes behind this observation. In this paper, we are studying the relationship between drug prescriptions, drug-drug interactions (DDIs) and patient mortality. Our focus is not so much on the number of prescribed drugs, the typical metric in polypharmacy research, but rather on the specific combinations of drugs leading to a DDI. To learn the space of real-world drug combinations, we first assessed the drug prescription landscape of the UK Biobank, a large patient data registry. We observed distinct drug constellation patterns driven by the UK Biobank participants' disease status. We show that these drug prescription clusters matter in terms of the number and types of expected DDIs, and may possibly explain observed differences in health outcomes.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.